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ABSTRACT
Enhancers, or cis-regulatory elements, are the principal determinants of spatiotemporal patterning of gene
expression. For reasons of clinical and research utility, it is desirable to build customized enhancers that
drive novel gene expression patterns, but currently, we largely rely on ‘‘found’’ genomic elements. Syn-
thetic enhancers, assembled from transcription factor binding sites taken from natural signal-regulated
enhancers, generally fail to behave like their wild-type counterparts when placed in transgenic animals,
suggesting that important aspects of enhancer function are still unexplored. As a step toward the creation
of a truly synthetic regulatory element, we have undertaken an extensive structure–function study of an
enhancer of the Drosophila decapentaplegic (dpp) gene that drives expression in the developing visceral
mesoderm (VM). Although considerable past efforts have been made to dissect the dppVM enhancer,
transgenic experiments presented here indicate that its activity cannot be explained by the known regu-
lators alone. dppVM contains multiple, previously uncharacterized, regulatory sites, some of which ex-
hibit functional redundancy. The results presented here suggest that even the best-studied enhancers must
be further dissected before they can be fully understood, and before faithful synthetic elements based on
them can be created. Implications for developmental genetics, mathematical modeling, and therapeutic
applications are discussed.
INTRODUCTION
ENHANCERS WERE FIRST IDENTIFIED as DNA sequencescapable of boosting the rate of transcription at a nearby
promoter, and were named for this quantitative property.1,2
It was later discovered that enhancers can also control the
spatiotemporal pattern of gene expression within tissues, that
they can function at great distances from the promoter being
regulated, and that a single gene can harbor many regulatory
elements.3 Enhancers are now recognized as principal reg-
ulators of gene expression in multicellular eukaryotes.4
As important as enhancers are to organisms for regulating
gene expression, they are no less useful to researchers and
clinicians who wish to experimentally manipulate gene ex-
pression in specific subsets of cells, or restrict the expression
patterns of therapeutic transgenes, and many ‘‘found’’
minimally characterized genomic elements lifted directly
from native sequences are currently used in a wide range of
cell-replacement and gene-therapy approaches for the
treatment of disease.5–11 For example, promising strategies
for the treatment of Parkinson’s and Alzheimer’s disease
incorporate the use of native enhancer elements, with the
goal of promoting neural survival or rescuing neural func-
tion.8 In one case, enhancers from the central nervous
system–specific intermediate filament gene nestin and the
signaling morphogen sonic hedgehog are used as tools to
drive embryonic stem cells to differentiate into progenitors
of specific subtypes for the purpose of therapeutic trans-
plantation.9 As a second example, approaches to the treat-
ment of myocardial ischemia have also included native
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tissue–specific enhancers.10 One particularly clever viral
gene therapy vector, aptly named the ‘‘vigilant vector,’’ in-
corporates both a hypoxia response element that upregulates
transcription when oxygen levels are low, and a heart-
specific promoter isolated from the myosin light chain
(MLC-2v).11 The use of tissue or cell type–specific enhancer
elements is a prominent theme in treatment strategies for a
wide variety of other disease types, including cancer, dia-
betes, and arthritis.10 In addition, while many advanced in-
ducible gene regulation systems are widely used in a variety
of gene therapy applications (including the tetracycline-
dependent regulatable gene expression system known as Tet-
ON and Tet-OFF), their versatility and wide-spread appeal are
in fact a direct result of the inclusion of cell type–specific or
organ-specific enhancer/promoters that are still very much
required for the specificity of transgene expression.10
As the incorporation of cell type–specific promoters in
gene therapy, cell replacement, and tissue engineering strat-
egies becomes more sophisticated, we expect that the need
to fine-tune the specificity of these elements and to minimize
their size will become more prominent, and the actual lim-
itations of our understanding of enhancer structure and
function will become more broadly apparent. We anticipate
that the ability to build truly ‘‘synthetic’’ versions of en-
hancers is a need just on the horizon, and a detailed under-
standing of how these ‘‘found’’ enhancer sequences function
on a base-by-base level will become much more necessary
as we attempt to mimic the real complexities of in vivo de-
velopmental signaling.
One might expect that, following the principle of combi-
natorial control, novel gene expression patterns could be
generated simply by combining transcription factor (TF)
binding sites in synthetic regulatory elements. This can be
easily accomplished in the context of cultured cells, where
even transfected constructs containing binding sites for a
single TF can respond robustly in the presence of that
factor.12 However, regulatory sequences inserted into a chro-
mosome, in the context of a multicellular organism, are
subject to much tighter restrictions on gene expression, and
generally require a surprisingly large number of transcrip-
tional inputs.12,13 In fact, in over 25 years of enhancer re-
search, published reports of robustly active synthetic
combinatorial enhancers, built ‘‘from scratch’’ by combining
binding sites for multiple TFs, and active in an appropriate
pattern in transgenic animals, are exceedingly rare.12–14 As it
turns out, real regulatory elements are subject to more com-
plex regulation than typical enhancer models predict. Take,
for example, the 480-bp Drosophila even-skipped (eve) stripe
2 enhancer, perhaps the most intensively studied develop-
mental enhancer and, literally, the textbook example of a
well-understood cis-regulatory element.15–17 Thirteen regu-
latory sites, bound by a total of five different TFs, have been
identified within the eve stripe 2 enhancer,18,19 and yet of the
remaining stretches of sequence between the clusters of
known TF binding sites, all are necessary for full enhancer
activity in vivo.19 After 20 years of study, the story of this
enhancer is still only half-told.
So is eve stripe 2 an unusually baroque element, or is it a
fairly typical example of an enhancer? To answer this
question, we have built synthetic versions of four previ-
ously characterized Drosophila developmental enhancers,
all with multiple known direct inputs, by combining the
known TF binding sites. We also present the results of an
extensive functional analysis of one of these, taken from
the Drosophila decapentaplegic (dpp) gene, which encodes
a TGF-b/BMP-family ligand and responds to Wnt signal-
ing in the embryonic visceral mesoderm (VM). The goals
of this portion of the study are (i) to determine the cis-
regulatory complexity of the enhancer and (ii) to build
minimal synthetic elements that recapitulate its transcrip-
tional activity in vivo.
MATERIALS AND METHODS
DNA cloning and mutagenesis
All constructs described in this report were subcloned
either into the pENTR/D-TOPO plasmid (Invitrogen,
Carlsbad, CA) by TOPO cloning or into the pBS-ENTR-
TOPO plasmid20 by traditional cloning, and then placed by
Gateway recombination cloning into the P-element lacZ
reporter vector Ganesh-Z1,20 which inserts pseudo-ran-
domly into the genome as a single copy.
Internal deletions of enhancers were created with overlap
extension PCR, or ‘‘gene sewing.’’21,22 More complex mu-
tations and synthetic enhancer constructs were created with
assembly PCR, in which short overlapping oligonucleotides
are annealed and assembled into long double-stranded
DNAs via PCR.23–25 Detailed protocols are available at
sitemaker.umich.edu/barolo/protocols. Full sequences of all
wild-type and mutagenized enhancers, synthetic constructs,
and PCR primers are available upon request.
Transgenesis
P-element transformation by embryo injection was per-
formed essentially as previously described.26 A slightly
modified protocol is available at sitemaker.umich.edu/
barolo/protocols. w1118 flies were used for transgenesis. To
eliminate the effect of genomic insertion site on gene expres-
sion, several independent transgenic lines bearing each con-
struct were examined, and representative results are shown.
Tissue preparation, staining, and microscopy
Staged Drosophila embryos were fixed in formalde-
hyde and subjected to RNA in situ hybridization with a
digoxigenin-labeled lacZ probe, essentially as previously
described.27 A slightly modified protocol is available at
sitemaker.umich.edu/barolo/protocols. Wing imaginal discs
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were dissected from crawling third-instar transgenic larvae,
fixed in glutaraldehyde, and stained for b-galactosidase
activity, as previously described.28 Images of stained em-
bryos and imaginal discs were obtained with an Olympus
BX51 microscope and an Olympus DP70 digital camera.
DNA sequence alignment
Orthologous Drosophila genomic sequences were iden-
tified by BLAST searches on the DroSpeGe website29
(http://insects.eugenes.org/species). dppVM orthologous se-
quences were initially aligned, as multiple smaller frag-
ments, with the web-based ClustalW program30 (www
.ebi.ac.uk/Tools/clustalw). Default settings were used, with
the following exceptions: the gap open penalty was set to 5,
and the gap extension penalty was set to 2.5. The ClustalW
text output was copied to Microsoft Word, where the sub-
alignments were merged, the alignment was amended by
hand in cases where conserved motifs were clearly mis-
aligned, and the large indels in region 4 were removed,
where indicated, to conserve space.
RESULTS
In vivo insufficiency of synthetic
signal-regulated enhancers
We were curious about the extent to which the activity and
pattern of various well-studied enhancers could be explained
by the described regulatory inputs. Specifically, we were
interested in cases where binding sites for specific regulatory
factors had been identified and shown to be essential for the
proper regulation of the enhancer, but where the sufficiency
of these combined inputs for enhancer activity had not been
tested. We built synthetic versions of four Drosophila de-
velopmental enhancers, consisting of multimerized binding
sites for the known regulatory TFs. The first is the proneural
enhancer of the E(spl)m4 gene, which is active in Notch-
responsive cells of proneural clusters in larval imaginal
discs, and depends on binding sites for Suppressor of Hair-
less [Su(H)] and Achaete/Scute bHLH proteins for its ac-
tivation31,32 (Fig. 1A). Our synthetic element, containing
multimerized high-affinity Su(H) and Achaete/Scute bind-
ing sites, failed to reproduce the E(spl)m4 proneural ex-
pression pattern in vivo (Fig. 1B).
The second enhancer we attempted to re-create was the
well-characterized, EGFR- and Notch-regulated sparkling
(spa) enhancer of the dPax2 gene, which is directly activated
by Su(H), Lozenge, and Pointed-P2 in presumptive cone
cells of the developing eye33,34 (Fig. 1C). Again, a synthetic
element composed of multiple high-affinity binding sites for
these TFs failed to recapitulate the expression of the native
enhancer (Fig. 1D). We have subsequently found that a
synthetic element in which the TF binding sites are taken
directly from the native spa enhancer, and are placed in their
FIG. 1. Synthetic versions of well-studied developmental en-
hancers fail to recapitulate their activity in vivo. All panels show
imaginal discs from larvae carrying lacZ reporter transgenes.
Reporter gene expression is visualized by X-gal staining. (A)
Proneural expression pattern in the developing wing driven by a
Notch-regulated enhancer of the E(spl)m4 gene, which contains
binding sites for Achaete/Scute [A] and Su(H) [S]. (B) A synthetic
version of the E(spl)m4 enhancer, containing multimerized high-
affinity A and S binding sites, does not produce an E(spl)m4-like
pattern. (C) Cone cell–specific expression pattern driven by the
sparkling (spa) enhancer of the dPax2 gene, which contains
binding sites for Lozenge [L], Su(H) [S], and Pointed-P2 [P]. (D)
A synthetic enhancer containing high-affinity L, P, and S binding
sites does not recapitulate dPax2 expression. (E) A disc-specific
enhancer of the dpp gene (dppD), containing binding sites for
Engrailed [E] and Ci [C], drives expression in Hedgehog-
responding cells of the developing wing. (F) A synthetic version
of dppD, containing only the E and C sites in their native spacing,
fails to drive gene expression in vivo.
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native arrangement and spacing, is inactive in vivo
(C. Swanson, N. Evans, and S.B., manuscript under review).
A disc-specific enhancer of the decapentaplegic gene,
dppD, responds to Hedgehog signaling in imaginal tissues
via Cubitus interruptus (Ci) binding sites, and is directly
repressed by Engrailed35 (Fig. 1E). Synthetic enhancer ex-
periments confirm the reported insufficiency of the Ci sites
of dppD,35 even when these sites are placed in their native
arrangement (Fig. 1F).
The fourth enhancer addressed in this study, dppVM, will
be discussed in the following section. In all four cases, the
known regulatory inputs, taken together, appear to be in-
sufficient for proper enhancer activity in vivo. This contrasts
with the results of numerous reporter gene experiments in
transfected cultured cells, in which a small number of
binding sites for a single TF (e.g., Su[H] or Ci/Gli binding
sites) are often sufficient to drive a strong transcriptional
response upon expression of that TF or stimulation of
the relevant signaling pathway.12,13 It appears that, at least
in these cases, transcriptional activation of a chromatin-
embedded gene, under normal cellular conditions, is not
simply or easily achieved.
The dppVM enhancer
A 419-bp genomic segment, located 9 kilobases (kb)
upstream of the coding sequence of the dpp gene, is capable
of driving reporter gene expression in dpp-positive cells in
parasegment 7 of the embryonic visceral mesoderm36,37
(Fig. 2B). This enhancer, referred to here as dppVM, con-
FIG. 2. In vivo functional analysis of the dpp visceral mesoderm enhancer, dppVM. (A) Map of the dpp locus. The dpp transcription
unit is depicted as boxes; protein-coding sequence is black. Arrows indicate promoters. Two enhancers of the dpp gene, the imaginal
disc enhancer dppD and the visceral mesoderm enhancer dppVM, are shown in gray. (B–I) Whole mount transgenic Drosophila
embryos in which lacZ reporter gene expression is detected by RNA in situ hybridization. Anterior is to the left. Black bars indicate
known or predicted protein binding sites, gray indicates wild-type uncharacterized sequence, dashed lines indicate deleted sequence, and
white (with a black border) indicates sequence that has been altered but not deleted. (B) Embryos carrying the wild-type, 419-bp dppVM
in the Ganesh-Z1 vector,30 driving lacZ expression in visceral mesoderm in parasegment 7. Left, lateral view; right, dorsal view; bottom;
diagram of enhancer and reporter gene. (C–G) Lateral views of embryos carrying mutant versions of dppVM (D1 through D5), in which
uncharacterized enhancer regions 1 through 5 are deleted, one at a time. No single deletion abolishes enhancer activity. (H) Dorsal view
of embryo carrying a ‘‘synthetic’’ 287-bp version of dppVM, in which the functionally significant Ubx, TCF, and Exd sites are placed
together, and all other enhancer sequences are deleted. (I) Dorsal view of embryo carrying construct m12345, in which the TF sites are
present in their normal arrangement and spacing, and the sequence of regions 1 through 5 is altered.
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tains predicted binding sites for the Hox protein Ultra-
bithorax (Ubx) and its cofactor Extradenticle (Exd), the
Wnt-responsive factor TCF, and the FoxF-related factor
Biniou (Bin); all four proteins directly bind to dppVM
in vitro.37–39 Ubx and Exd directly activate transcription via
dppVM,37,40 while TCF acts as a Wnt-regulated transcrip-
tional switch, activating dpp in Wnt-responding visceral
mesoderm cells and repressing dpp in cells not receiving
Wnt signaling.38 However, neither ectopic Ubx/Exd nor
ectopic Wnt signaling is sufficient to drive enhancer ex-
pression outside the visceral mesoderm, and dppVM is not
active in other Wnt-responding or Ubx/Exd-expressing
cells.37,38,40 Similarly, Bin is required, but is not sufficient,
for activation of dpp in the visceral mesoderm.39
To test the sufficiency of these regulatory inputs for en-
hancer activity, we engineered a series of five deletions in
sequence of dppVM (named D1–D5; Fig. 2C–G), which
together cover all of the previously uncharacterized se-
quence of the enhancer. None of these five deletions abol-
ished enhancer activity, even one (D2) that removed the only
known Bin binding site (Fig. 2D). Of this series of con-
structs, only D3 showed a noticeable difference from the
wild-type element, driving a slightly narrower stripe of ex-
pression (Fig. 2E, cf. panel B).
Based on these results, it might be concluded that none of
the deleted regions is absolutely required for enhancer ac-
tivity. However, when all five regions were deleted at once,
resulting in the minimal ‘‘synthetic’’ construct synthA, en-
hancer activity in vivo was destroyed (Fig. 2H). To account
for the possibility that changes in spacing among TF binding
sites are responsible for this failure of activation, we created
another synthetic element, m12345, in which regions 1
through 5 were mutated (by changing every other base pair
to its noncomplementary transversion: A to C, C to A, G to
T, and T to G), but in which the spacing and arrangement of
the remaining TF binding sites was normal. This construct
was also inactive (Fig. 2I).
Later experiments in which the GC content of mutated
enhancer sequences is preserved (see Fig. 4) indicate that it is
not merely the local GC content (and therefore the DNA
rigidity) of these regions that is important, but rather the
specific sequence within these regions. This is at least con-
sistent with the possibility that dppVM harbors functionally
importantbindingsites foras-yet-unknownregulatoryfactors.
Taken together, these results suggest that additional reg-
ulatory sequences beyond the known TF sites are required,
but that there is functional redundancy among these se-
quences such that no single subelement is essential. The
proposal of functional redundancy is further supported by
the fact that the Bin site is essential in the context of a 261-bp
truncated version of the enhancer that extends only to within
region 4,22 but that site is not essential in the 419-bp frag-
ment (Fig. 2D). We therefore conclude that the 30 end of the
enhancer, a region that contains no known or predicted Bin
binding sites, harbors a regulatory site or sites that are
functionally redundant with the Bin site in region 2.
Evolutionary dynamics of regulatory sequences
Comparing orthologous sequences from related species
allows us to observe how regulatory DNA changes over
time. Evolutionary sequence alignments can also be useful
in enhancer dissection, since functionally critical regulatory
sequences are often, though not always,41 relatively well
conserved. Thanks to the recent sequencing of the genomes
of twelve Drosophila species, the evolution of the dppVM
enhancer within that genus can be visualized (Fig. 3). As
with many aligned enhancer sequences, the following fea-
tures are observed:
Known regulatory binding sites are generally well con-
served (more so in dppVM than in many other enhancers,
in our experience).
Such sites are often (but not always) clustered within small
islands of highly conserved sequence, within which there
is little or no change in binding site spacing.
The linear order of conserved sequence islands is main-
tained throughout the lineage.
Uncharacterized sequences (i.e., those lacking known TF
binding sites) range from rapidly evolving to very well
conserved.
The enhancer is subject to many ‘‘indels’’ (relative in-
sertions and deletions), causing the orthologs to vary dra-
matically in size (from 418 to 1425 bp, a 3.4-fold range), and
resulting in variable distances between neighboring islands
of conserved sequence. As in many other enhancers, the
distance between closely spaced binding sites (such as
Ubx294 and Exd305) is sometimes well conserved, which
could reflect important pairwise interactions between
neighboring TFs or their co-factors. By contrast, there ap-
pears to be little selection pressure maintaining the relative
spacing of these small clusters of TF binding sites (see re-
gions 1 through 5), which could in turn suggest a lack of rigid
structure within the enhancer as a whole. It is also possible,
however, that the enhancer and its bound regulators do form
a precise three-dimensional structure, and that ‘‘spacer’’
sequences are merely ‘‘looped out,’’ rendering their length
relatively unimportant. The generally compact size of known
enhancers, along with studies of functional interactions
among TFs, suggests that there are usually upper limits of
binding site spacing within an enhancer, beyond which the
activities of its bound regulators fail to cohere into a unified
signal to the promoter. This may not always be the case,
however,42 and it is possible that our current views on en-
hancer size are skewed by sample bias, both in the design of
experiments and in the publication of results.
Another notable sequence feature is the presence of well-
conserved repeats at the 50 end of region 3, first noticed by Sun
et al.37 This repeated octamer sequence, which we define as
ATGYTGCA (where Y¼C or T), occurs as two overlapping
repeats, followed by another sequence with a one-base mis-
match, in the 50 end of region 3 (called region 3a). Of the
dppVM orthologs in the 12 sequenced Drosophila species,
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FIG. 3. Evolutionary alignment of the sequence of dppVM across 12 Drosophila species: mel, D. melanogaster; sec, D. sechellia; sim,
D. simulans; yak, D. yakuba; ere, D. erecta; ana, D. ananassae; pse, D. pseudoobscura; per, D. persimilis; wil, D. willistoni; vir, D. virilis;
moj, D. mojavensis; gri, D. grimshawi. Dashes indicate gaps added to align orthologous sequences. Known and predicted protein binding
sites are labeled and highlighted in black; the number indicates position, given in base pairs from the 50 end of the enhancer. Regions 1
through 5 are indicated with arrows. ATGYTGCA repeats are in bold and underlined. Bases identical to the D. melanogaster sequence are
shaded gray. Numbers after the sequences represent the length of the sequences, measured from the PstI site to the XbaI site.
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all contain from one to four instances of this octamer (bold
and underlined in Fig. 3). In four species, octamers are found
both in region 3a and at the 50 end of region 4 (region 4a). We
investigated the possible function of these sequences in fur-
ther mutagenesis experiments (below).
Combinatorial mutations reveal novel,
functionally redundant activities
Certain previously uncharacterized sequences within
dppVM (i.e., those sequences for which no binding factor
has been identified) are highly conserved throughout the
genus Drosophila, which could reflect an important func-
tional role for those sites. However, as we have shown
(Fig. 1), none of these novel conserved sites is necessary for
enhancer function in the context of the full-length dppVM
element. For example, a sequence that we called region 5c,
at the 30 end of region 5, is highly conserved (Fig. 3), but is
not necessary for dppVM enhancer activity (Fig. 2G).
However, we found that combining the deletion of region 5c
with the deletion of region 1 caused a severe reduction in
reporter gene expression (Fig. 4B, cf. panel A), despite the
fact that both sequences are dispensable when removed in-
dividually. We conclude that these regulatory regions,
though dissimilar at the sequence level, are functionally
redundant.
We also investigated the functional role of the AT-
GYTGCA octamer repeats found in region 3a (and in some
species, also in region 4a). Mutations in region 3a do not
abolish dppVM activity in vivo,21 nor does a combination of
mutations in regions 3a and 4a (Fig. 4C). When these two
mutations were combined with the deletion of region 1,
however, enhancer activity was nearly completely lost (Fig.
4D). Here again, we observed functional redundancies
among regulatory sequences with little or no sequence
similarity.
Two routes to a near-minimal functional enhancer
As a starting point in our next attempt to create a func-
tional but minimal version of the dppVM enhancer, we built
a mutant element in which all of the known or predicted
Ubx, Exd, Bin, and TCF sites are maintained, and are placed
in their native spacing, but the interstitial sequences are
mutated such that the GC content of each region is preserved
(every other base altered; A to T, T to A, C to G, and G to C).
This construct (mut-GC, UþEþBþT) was inactive in vivo
(Fig. 4E). However, restoring regions 3a and 4a to the con-
struct (mut-GC, UþEþBþTþ 3aþ 4a) largely, though
not completely, rescued its activity (Fig. 4F).
Interestingly, creating a tandem duplication of the con-
struct mut-GC, UþEþBþT failed to rescue its activity
(Fig. 4G). The fact that adding a second copy of each pre-
viously identified regulatory binding site did not reconstitute
enhancer activity, while adding regions 3a and 4a did (Fig.
4F), suggests that these novel regulatory sites may contrib-
ute a qualitatively distinct activity that is essential for
enhancer function, and that cannot be substituted with ad-
ditional binding sites for the known regulatory factors.
A second approach to building a functional minimal en-
hancer took advantage of evolutionary conservation data.
We created a 287-bp synthetic element containing only the
FIG. 4. Combinatorial mutations reveal functional redundancy
in novel regulatory sequences within dppVM. Embryos are stained
and presented as in Figure 2. (A) Wild-type dppVM. (B) Lateral
view of embryo carrying a mutated dppVM lacking region 1 and
the 30 third of region 5 (region 5c). (C) Dorsal view of embryo
carrying an enhancer in which the ATGYTGCA repeats (region
3b) and similar sequences (region 4a) have been altered. (D)
Combining the deletion of region 1 with mutations in regions 3b
and 4a causes a significant loss of enhancer activity. (E) A mu-
tated enhancer in which all known or predicted binding sites
(UbxþExdþBinþTCF) are preserved, but all other sequences
are altered such that the wild-type GC content is maintained. (F)
A construct similar to the previous, but with the addition of the
wild-type ATGYTGCA repeats (3b) and related sequences (4a).
Enhancer activity is restored. (G) Two tandem copies of the
construct shown in panel E are insufficient for enhancer activity.
(H) A construct containing only the most highly conserved se-
quences from dppVM shows visceral mesoderm activity.
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most highly conserved sequences, with all other sequences
deleted. This construct (dppVM-conserved only) drove re-
porter gene expression in the proper pattern, though not at
levels equal to the wild-type element (Fig. 4H). This is
consistent with the proposal, stated above, that spacing
among islands of conserved sequence does not play a critical
role in the function of this enhancer, although it may make a
minor contribution with respect to proper quantitative levels
of gene expression.
Toward a truly minimal, yet functional,
synthetic enhancer
The previous section describes two methods by which we
created functional (if not full-strength) elements lacking
a large proportion of the sequence of the native en-
hancer. Building on these findings, we then created an even
smaller element (called synthB), containing only those se-
quences shared by both mut-GC, UþEþBþTþ 3aþ 4a
and dppVM-conserved only, with the addition of a second,
highly conserved TCF site located just 30 of dppVM (see Fig.
3 for sequence). The 205-bp synthB element (diagrammed in
Fig. 5A; sequence given in panel E) activated gene expres-
sion in the proper pattern, and even more intensely than the
wild-type 419-bp enhancer (Fig. 5C; cf. panel B).
At 205 bp, synthB is half the length of the native enhancer
it is derived from. We made several attempts to further re-
duce the size of our synthetic element (synthC through
synthL), but found that nearly all of the regulatory sequences
in synthB make a significant contribution to its activity
in vivo (Fig. 5A). Only region 4a could be removed without
affecting gene expression levels (synthG). The lower size
limit for a full-strength synthetic dppVM element, therefore,
appears to be roughly half the length of the natural enhancer.
Several of our synthetic enhancer experiments provide
evidence for the functional significance of the octamer re-
peats (Fig. 5A; synthF, -K, and -L), at least in the context of a
minimal enhancer construct. However, as mentioned above,
the octamers are not necessary for the activity of the full-
length dppVM. This could be due to functional redundancy
between the octamers and sequences within dppVM that
were excluded from the synthetic constructs.
DISCUSSION
Building enhancers from spare parts
We have demonstrated that dppVM cannot in fact be re-
duced to a functional synthetic element composed simply of
all of the currently characterized regulatory sites. We have
FIG. 5. Toward a functional
‘‘synthetic’’ visceral mesoderm
enhancer. (A) Diagrams (to
scale) of a series of constructs
(synthA through synthL) con-
taining subsets of sequences
from dppVM. Arrowheads in-
dicate sites of deletions, rela-
tive to constructs shown above.
Strength of reporter gene ex-
pression in visceral mesoderm
is summarized on the right,
where ‘‘þþþ ’’ indicates
wild-type expression levels and
‘‘–’’ indicates no detectable
expression. (B–D) Dorsal
views of embryos carrying
constructs dppVM-wt, synthB,
and synthK. (E) Annotated se-
quence of the synthB construct.
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also shown this to be true of three other well-characterized,
signal-regulated developmental enhancers: a proneural en-
hancer of the E(spl)m4 gene, an eye enhancer of the dPax2
gene, and an imaginal disc enhancer of dpp (Fig. 1). As
previously discussed, the extensively dissected eve stripe 2
enhancer also cannot be similarly reduced.19 Our attempt to
further simplify and reduce the dppVM enhancer has re-
vealed the presence of multiple unknown functionally re-
dundant regulatory elements in addition to binding sites
for the four known regulators, and our goal of generating a
truly ‘‘synthetic’’ functional enhancer remains, to date, un-
achieved. It is possible that the requirement of a unexpect-
edly large number of transcriptional inputs reflects a
requirement for a minimum number of activating TFs, each
of which contributes a small amount of ‘‘activation activ-
ity,’’ before a cumulative threshold is crossed and activation
can occur. Alternatively, it may be that different activating
TFs recruit different biochemical activities to the enhancer
(such as chromatin remodeling, DNA looping, subnuclear
localization of the locus, etc.), all of which must act in
concert, or sequentially, to stimulate the promoter. In addi-
tion to the well-known classes of cell type–specific TFs,
which often recruit chromatin-remodeling cofactors, there
may also be more general enhancer-binding factors with
different biochemical properties still awaiting discovery.
Insights from ‘‘promoter bashing’’
It is important to emphasize how substantially this work
contradicts the general perception of our level of under-
standing of enhancer structure and function. The conven-
tional wisdom among many researchers is that, with the
discovery of combinatorial control, the enhancer is essen-
tially ‘‘solved,’’ and the rest is mere detail. As we have
demonstrated here, there is still much of interest to learn,
even at the level of cataloging and characterizing regulatory
DNA sites. Simplified cartoon models of enhancer function
may have led to a mistaken perception that ‘‘promoter
bashing,’’ as mutagenesis of reporter genes is sometimes
referred called, has reached the end of its usefulness, and that
in silico or systems-biology approaches will inevitably
render small-scale functional studies unnecessary. As this
work has demonstrated, not only does much remain to be
discovered at the functional level, but much further effort
will be required before fully understood synthetic constructs
can be designed that can mimic the real complexities of
in vivo developmental signaling. Such capabilities are be-
coming increasingly more desirable for the development of
more sophisticated therapeutic tissue repair and regeneration
strategies. In addition, the results presented here have po-
tential implications for the development of mathematical
models of the in vivo activity of complex regulatory path-
ways. Models relying on a simple Boolean logic of cis-
regulatory input may, in the end, be insufficient to explain
natural enhancers—or at the very least, the number of re-
quired terms may be greater than expected.43,44
Although we cannot yet successfully recapitulate existing
expression patterns without including ‘‘mystery’’ sequences
(i.e., sequences without known direct binding factors), re-
sults such as those presented here still present significant
opportunities for further discovery in molecular biology. For
example, by identifying and characterizing the unknown
regulators of dppVM, particularly the repeated octamer, we
may discover new regulatory factors that play significant
roles in the development of the tissues where those en-
hancers are active. Further analyses of the other enhancer
elements examined here have already begun to yield results
with interesting implications for developmental genetics,
including evidence suggesting that a subelement of the
sparkling enhancer is specifically required for action at
a distance from the promoter (C. Swanson, N. Evans, and
S.B., manuscript under review), and evidence for the special
importance of low-affinity TF binding sites in signal-
responsive enhancers (D. Parker and S.B., manuscript in
preparation). We hope and expect that once the regulatory
inputs of a few test enhancers have been comprehensively
identified and characterized, this function-based reverse-
engineering approach will lead to a better understanding of
mechanisms of transcriptional control, an improved ability
to mathematically model and predict in vivo transcriptional
networks, and, ultimately, the advancement of therapeutic
transgene strategies via the creation of custom-built cell–
and tissue–specific enhancers.
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